|
1.
|
Hedden A, Müller V and Jensen EV: A new
interpretation of antiestrogen action. Ann NY Acad Sci.
761:109–120. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Klinge CM: Estrogen receptor interaction
with estrogen response elements. Nucleic Acids Res. 29:2905–2919.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Kushner PJ, Agard DA, Greene GL, et al:
Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol.
74:311–317. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Safe S: Transcriptional activation of
genes by 17β-estradiol through estrogen receptor-Sp1 interactions.
Vitam Horm. 62:231–252. 2001.
|
|
5.
|
Dotzlaq H, Leygue E, Watson PH and Murphy
LC: Expression of estrogen receptor-β in human breast tumors. J
Clin Endocrinol Metab. 82:2371–2374. 1997.
|
|
6.
|
Ali S and Coombes RC: Estrogen receptor
alpha in human breast cancer: occurrence and significance. J
Mammary Gland Biol Neoplasia. 5:271–281. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Korach KS, Couse JF, Curtis SW, et al:
Estrogen receptor gene disruption: molecular characterization and
experimental and clinical phenotypes. Recent Progr Horm Res.
51:1591996.PubMed/NCBI
|
|
8.
|
Bocchinfuso WP and Korach KS: Mammary
gland development and tumorigenesis in estrogen receptor knockout
mice. J Mammary Gland Biol Neoplasia. 2:323–334. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Shaaban AM, O’Neill PA, Davies MPA, et al:
Declining estrogen receptor-[beta] expression defines malignant
progression of human breast neoplasia. American J Surg Pathol.
27:1502–1512. 2003.
|
|
10.
|
Gralow JR: Optimizing the treatment of
metastatic breast cancer. Breast Cancer Res Treat. 89:9–15. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Shang Y and Brown M: Molecular
determinants for the tissue specificity of SERMs. Science.
295:2465–2468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Osborne CK, Zhao HH and Fuqua SAW:
Selective estrogen receptor modulators: structure, function, and
clinical use. J Clin Oncol. 18:3172–3186. 2000.PubMed/NCBI
|
|
13.
|
McCarthy TL, Clough ME, Gundberg CM and
Centrella M: Expression of an estrogen receptor agonist in
differentiating osteoblast cultures. Proc Natl Acad Sci USA.
105:7022–7027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Cassady JM, Baird WM and Chang CJ: Natural
products as a source of potential cancer chemotherapeutic and
chemopreventive agents. J Nat Prod. 53:23–41. 1990.PubMed/NCBI
|
|
15.
|
Zhang N, Kong X, Yan S, Yuan C and Yang Q:
Huaier aqueous extract inhibits proliferation of breast cancer
cells by inducing apoptosis. Cancer Sci. 101:2375–2383. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Wang X, Zhang N, Huo Q and Yang Q:
Anti-angiogenic and antitumor activities of Huaier aqueous extract.
Oncol Rep. 28:1167–1175. 2012.PubMed/NCBI
|
|
17.
|
Ren J, Zheng C, Feng G, et al: Inhibitory
effect of extract of fungi of Huaier on hepatocellular carcinoma
cells. J Huazhong Univ Sci Technolog Med Sci. 29:198–201. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Xu X, Wei Q, Wang K, et al: Anticancer
effects of Huaier are associated with down-regulation of P53. Asian
Pac J Cancer Prev. 12:2251–2254. 2011.PubMed/NCBI
|
|
19.
|
Sun Y, Sun T, Wang F, et al: A
polysaccharide from the fungi of Huaier exhibits anti-tumor
potential and immunomodulatory effects. Carbohydr Polym.
92:577–582. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lippman M, Bolan G and Huff K: The effects
of estrogens and antiestrogens on hormone-responsive human breast
cancer in long-term tissue culture. Cancer Res. 36:4595–4601.
1976.PubMed/NCBI
|
|
21.
|
Dupont J, Karas M and LeRoith D: The
potentiation of estrogen on insulin-like growth factor I action in
MCF-7 human breast cancer cells includes cell cycle components. J
Biol Chem. 275:35893–35901. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zhu J, Li X, Kong X, et al: Testin is a
tumor suppressor and prognostic marker in breast cancer. Cancer
Sci. 103:2092–2101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Altucci L, Addeo R, Cicatiello L, et al:
17beta-estradiol induces cyclin D1 gene transcription,
p36D1-p34cdk4 complex activation and p105Rb phosphorylation during
mitogenic stimulation of G (1)-arrested human breast cancer cells.
Oncogene. 12:23151996.
|
|
24.
|
Kodama F, Greene GL and Salmon SE:
Relation of estrogen receptor expression to clonal growth and
antiestrogen effects on human breast cancer cells. Cancer Res.
45:2720–2724. 1985.PubMed/NCBI
|
|
25.
|
Lu J, Pierron A and Ravid K: An adenosine
analogue, IB-MECA, down-regulates estrogen receptor α and
suppresses human breast cancer cell proliferation. Cancer Res.
63:6413–6423. 2003.PubMed/NCBI
|
|
26.
|
Wormke M, Stoner M, Saville B, et al: The
aryl hydrocarbon receptor mediates degradation of estrogen receptor
α through activation of proteasomes. Mol Cell Biol. 23:1843–1855.
2003.
|
|
27.
|
Wijayaratne AL and McDonnell DP: The human
estrogen receptor-α is a ubiquitinated protein whose stability is
affected differentially by agonists, antagonists, and selective
estrogen receptor modulators. J Biol Chem. 276:35684–35692.
2001.
|
|
28.
|
Horwitz KB, Koseki Y and McGuire WL:
Estrogen control of progesterone receptor in human breast cancer:
role of estradiol and antiestrogen. Endocrinology. 103:1742–1751.
1978. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Dauvois S, White R and Parker MG: The
antiestrogen ICI 182780 disrupts estrogen receptor
nucleocytoplasmic shuttling. J Cell Sci. 106:1377–1388.
1993.PubMed/NCBI
|
|
30.
|
Baker P, Wilton J, Jones C, Stenzel D,
Watson N and Smith G: Bile acids influence the growth, oestrogen
receptor and oestrogen-regulated proteins of MCF-7 human breast
cancer cells. Br J Cancer. 65:5661992. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Horwitz KB, Mockus MB and Lessey BA:
Variant T47D human breast cancer cells with high
progesterone-receptor levels despite estrogen and antiestrogen
resistance. Cell. 28:633–642. 1982. View Article : Google Scholar
|
|
32.
|
Rubio M, Werbajh S, Cafferata E, et al:
TNF-alpha enhances estrogen-induced cell proliferation of
estrogen-dependent breast tumor cells through a complex containing
nuclear factor-kappa B. Oncogene. 25:1367–1377. 2005. View Article : Google Scholar
|
|
33.
|
Fisher B, Costantino JP, Wickerham DL, et
al: Tamoxifen for prevention of breast cancer: report of the
National Surgical Adjuvant Breast and Bowel Project P-1 Study. J
Natl Cancer Inst. 90:1371–1388. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Ali S and Coombes RC: Endocrine-responsive
breast cancer and strategies for combating resistance. Nat Rev
Cancer. 2:101–112. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Yao K and Jordan VC: Questions about
tamoxifen and the future use of antiestrogens. Oncologist.
3:104–110. 1998.PubMed/NCBI
|
|
36.
|
Cortesi L, De Matteis E, Rashid I, et al:
Distribution of second primary malignancies suggests a
bidirectional effect between breast and endometrial cancer: a
population-based study. Int J Gynecol Cancer. 19:13582009.
View Article : Google Scholar
|
|
37.
|
Gutierrez MC, Detre S, Johnston S, et al:
Molecular changes in tamoxifen-resistant breast cancer:
relationship between estrogen receptor, HER-2, and p38
mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005.
View Article : Google Scholar
|
|
38.
|
Levin ER: Bidirectional signaling between
the estrogen receptor and the epidermal growth factor receptor. Mol
Endocrinol. 17:309–317. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Osborne C, Wakeling A and Nicholson R:
Fulvestrant: an oestrogen receptor antagonist with a novel
mechanism of action. Br J Cancer. 90:S2–S6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Buijs C, de Vries EG, Mourits MJ and
Willemse PH: The influence of endocrine treatments for breast
cancer on health-related quality of life. Cancer Treat Rev.
34:640–655. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Klinge CM: Estrogen receptor interaction
with co-activators and co-repressors. Steroids. 65:227–251. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Hsu SM, Chen YC and Jiang MC:
17β-estradiol inhibits tumor necrosis factor-α-induced nuclear
factor-κB activation by increasing nuclear factor-κB p105 level in
MCF-7 breast cancer cells. Biochem Biophys Res Commun. 279:47–52.
2000.
|
